Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels
The DOI matches its Crossref record; 63 of the 68 references it cites were found in a registry or an index.
Abstract
As men age, serum testosterone levels decrease, a factor that may contribute to some aspects of age-related physiological deterioration. Although androgen replacement has been shown to have beneficial effects in frankly hypogonadal men, its use in elderly men with borderline hypogonadism is controversial. Furthermore, current testosterone replacement methods have important limitations. We investigated the ability of the orally administered aromatase inhibitor, anastrozole, to increase endogenous testosterone production in 37 elderly men (aged 62–74 yr) with screening serum testosterone levels less than 350 ng/dl. Subjects were randomized in a double-blind fashion to the following 12-wk oral regimens: group 1: anastrozole 1 mg daily (n = 12); group 2: anastrozole 1 mg twice weekly (n = 11); and group 3: placebo daily (n = 14). Hormone levels, quality of life (MOS Short-Form Health Survey), sexual function (International Index of Erectile Function), benign prostate hyperplasia severity (American Urological Association Symptom Index Score), prostate-specific antigen, and measures of safety were compared among groups. Mean ± sd bioavailable testosterone increased from 99 ± 31 to 207 ± 65 ng/dl in group 1 and from 115 ± 37 to 178 ± 55 ng/dl in group 2 (P < 0.001 vs. placebo for both groups and P = 0.054 group 1 vs. group 2). Total testosterone levels increased from 343 ± 61 to 572 ± 139 ng/dl in group 1 and from 397 ± 106 to 520 ± 91 ng/dl in group 2 (P < 0.001 vs. placebo for both groups and P = 0.012 group 1 vs. group 2). Serum estradiol levels decreased from 26 ± 8 to 17 ± 6 pg/ml in group 1 and from 27 ± 8 to 17 ± 5 pg/ml in group 2 (P < 0.001 vs. placebo for both groups and P = NS group 1 vs. group 2). Serum LH levels increased from 5.1 ± 4.8 to 7.9 ± 6.5 U/liter and from 4.1 ± 1.6 to 7.2 ± 2.8 U/liter in groups 1 and 2, respectively (P = 0.007 group 1 vs. placebo, P = 0.003 group 2 vs. placebo, and P = NS group 1 vs. group 2). Scores for hematocrit, MOS Short-Form Health Survey, International Index of Erectile Function, and American Urological Association Symptom Index Score did not change. Serum prostate-specific antigen levels increased in group 2 only (1.7 ± 1.0 to 2.2 ± 1.5 ng/ml, P = 0.031, compared with placebo). These data demonstrate that aromatase inhibition increases serum bioavailable and total testosterone levels to the youthful normal range in older men with mild hypogonadism. Serum estradiol levels decrease modestly but remain within the normal male range. The physiological consequences of these changes remain to be determined.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These compounds have been shown to raise testosterone levels in hypogonadal men and are also orally administered (64-66).”
From Non-testosterone management of male hypogonadism: an examination of the existing literature (2020) · cites this paper as [65]
In the citing paper
“Aromatase inhibitors effectively delay epiphysial maturation in boys and improve testosterone levels in adult men”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [29]
In the citing paper
“In men third-generation aromatase inhibitors will decrease the mean plasma estradiol/testosterone ratio by 77% [28,29].”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [29]
In the citing paper
“Lowering estradiol levels, by administering an aromatase inhibitor, is associated with an increase in levels of LH, follicle-stimulating hormone (FSH) and testosterone [28,29].”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [29]
In the citing paper
“Although aromatase inhibition by anastrozole and letrozole is reported to be close to 100%, administration of these inhibitors to men will not suppress plasma estradiol levels completely.”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [29]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997) · Urology · doi:10.1016/s0090-4295(97)00238-0 · Cited by 5,849
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Feldman, H. A., Longcope, C., Derby, C. A., Johannes, C. B., Araujo, A. B., Coviello, A. D., Bremner, W. J., & McKinlay, J. B. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8201 · Cited by 1,861
Self-citationGRAY, A., FELDMAN, H. A., MCKINLAY, J. B., & LONGCOPE, C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1016 · Cited by 1,118
Self-citationTestosterone Replacement in Older Hypogonadal Men: A 12-Month Randomized Controlled Trial
Sih, R. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.6.1661 · Cited by 922
Morley, J. E., Kaiser, F. E., Perry, H. M., Patrick, P., Morley, P. M. K., Stauber, P. M., Vellas, B., Baumgartner, R. N., & Garry, P. J. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90057-3 · Cited by 830
Effects of testosterone supplementation in the aging male
Tenover, J. S. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.4.1092 · Cited by 768
Falahati-Nini, A., Riggs, B. L., Atkinson, E. J., O’Fallon, W. M., Eastell, R., & Khosla, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10942 · Cited by 757
Research works printed but not linked: 1
- Med Lett Drugs Ther, 42, 49
Cited by
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
Epoxide hydrolases: their roles and interactions with lipid metabolism
Newman, J. W., Morisseau, C., & Hammock, B. D. (2005) · Progress in Lipid Research · doi:10.1016/j.plipres.2004.10.001 · Cited by 474
Oestrogens and spermatogenesis
Carreau, S., & Hess, R. A. (2010) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2009.0235 · Cited by 307
Traish, A. M., Goldstein, I., & Kim, N. N. (2007) · European Urology · doi:10.1016/j.eururo.2007.02.034 · Cited by 268
Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., & Salonen, J. T. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0970 · Cited by 230
“Consistent with this hypothesis, the aromatase inhibitor anastrozole has been shown to increase total and bioavailable testosterone levels in elderly men with low testosterone levels (47).”
Background
Metadata
- Authors
- Leder, B. Z., Rohrer, J. L., Rubin, S. D., Gallo, J., & Longcope, C.
- Affiliations
- Massachusetts General Hospital (US)
- AstraZeneca (United States) (US)
- AstraZeneca Pharmaceuticals (S.D.R., J.G.), Wilmington, Delaware 19850
- University of Massachusetts Chan Medical School (US)
- ORCID
- Leder, Benjamin Z.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-03-01
- Volume
- 89
- Issue
- 3
- Pages
- 1174-1180
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2117332496
- Semantic Scholar
- aedcb017eb7fc20eca8962b9ec633cc90042cd64
- Cited by
- 149
- References
- 68
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 5 · 2020: 7 · 2019: 8 · 2018: 5 · 2017: 3 · 2016: 10 · 2015: 8 · 2014: 7 · 2013: 6 · 2012: 5
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Center for Research Resources (K23 RR 16310, K23RR016310)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Keywords
- anastrozole, aromatase inhibitors, older men, androgen deficiency, testosterone replacement therapy, estradiol suppression, luteinizing hormone, sexual function, erectile function, benign prostatic hyperplasia, quality of life, adverse effects, drug safety, age-related testosterone decline, prostate-specific antigen, LH/FSH ratio
- MeSH terms
- Anastrozole, Aged, Aging, Enzyme Inhibitors, Estrogens, Humans, Hypogonadism, Male, Middle Aged, Nitriles, Quality of Life, Testosterone, Triazoles, Treatment Outcome, Aromatase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels. https://app.cochat.ai/papers/10.1210/jc.2003-031467
- The paper
- Leder, B. Z., Rohrer, J. L., Rubin, S. D., Gallo, J., & Longcope, C. (2004). Effects of Aromatase Inhibition in Elderly Men with Low or Borderline-Low Serum Testosterone Levels. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2003-031467
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.